Univariable and MVAs of factors associated with PFS
| Factor . | Level . | n . | Univariable analysis HR (95% CI) . | P value . | MVA HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| MIPI score at diagnosis | High risk | 30 | 2.58 (1.43-4.65) | .002 | 2.56 (1.43-4.65) | .002 |
| Low/intermediate risk | 31 | — | — | |||
| TP53 alterations at diagnosis∗ | Yes | 21 | 1.39 (0.73-2.66) | .317 | ||
| No | 22 | — | ||||
| MIPI score before venetoclax | High risk | 35 | 1.24 (0.72-2.11) | .437 | ||
| Low/intermediate risk | 32 | — | — | |||
| Complex karyotype before venetoclax∗ | Yes | 10 | 1.17 (0.47-2.91) | .742 | ||
| No | 17 | — | ||||
| TP53 alterations before venetoclax∗ | Yes | 10 | 1.28 (0.55-2.84) | .556 | ||
| No | 20 | — | ||||
| Blastoid/pleomorphic before venetoclax | Yes | 29 | 1.10 (0.64-1.89) | .732 | ||
| No | 35 | — | ||||
| Lines of treatment before venetoclax | >3 | 24 | 1.15 (0.69-1.92) | .587 | ||
| ≤3 | 56 | — | ||||
| POD24 | Yes | 39 | 1.49 (0.91-2.44) | .116 | ||
| No | 38 | — | ||||
| Best response to last therapy before venetoclax | CR, PR | 33 | 0.62 (0.37-1.03) | .065 | ||
| SD, PD | 41 | — | ||||
| Best response to BTKi | CR, PR | 45 | 0.83 (0.49-1.40) | .483 | ||
| SD, PD | 24 | — | ||||
| Duration of treatment with BTKi, mo | >6 | 36 | 0.68 (0.41-1.12) | .128 | ||
| ≤6 | 34 | — | ||||
| Reason for stopping BTKi | PD | 59 | 1.21 (0.58-2.52) | .611 | ||
| Toxicity | 12 | — | ||||
| Duration of treatment with last therapy before venetoclax, mo | >4 | 35 | 0.68 (0.42-1.11) | .125 | ||
| ≤4 | 43 | — | ||||
| Venetoclax highest dose received, mg | ≥400 | 59 | 1.20 (0.64-2.25) | .571 | ||
| <400 | 17 | — | ||||
| Venetoclax combined with other agents | Yes | 31 | 0.67 (0.40-1.10) | .115 | ||
| No | 49 | — |
| Factor . | Level . | n . | Univariable analysis HR (95% CI) . | P value . | MVA HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| MIPI score at diagnosis | High risk | 30 | 2.58 (1.43-4.65) | .002 | 2.56 (1.43-4.65) | .002 |
| Low/intermediate risk | 31 | — | — | |||
| TP53 alterations at diagnosis∗ | Yes | 21 | 1.39 (0.73-2.66) | .317 | ||
| No | 22 | — | ||||
| MIPI score before venetoclax | High risk | 35 | 1.24 (0.72-2.11) | .437 | ||
| Low/intermediate risk | 32 | — | — | |||
| Complex karyotype before venetoclax∗ | Yes | 10 | 1.17 (0.47-2.91) | .742 | ||
| No | 17 | — | ||||
| TP53 alterations before venetoclax∗ | Yes | 10 | 1.28 (0.55-2.84) | .556 | ||
| No | 20 | — | ||||
| Blastoid/pleomorphic before venetoclax | Yes | 29 | 1.10 (0.64-1.89) | .732 | ||
| No | 35 | — | ||||
| Lines of treatment before venetoclax | >3 | 24 | 1.15 (0.69-1.92) | .587 | ||
| ≤3 | 56 | — | ||||
| POD24 | Yes | 39 | 1.49 (0.91-2.44) | .116 | ||
| No | 38 | — | ||||
| Best response to last therapy before venetoclax | CR, PR | 33 | 0.62 (0.37-1.03) | .065 | ||
| SD, PD | 41 | — | ||||
| Best response to BTKi | CR, PR | 45 | 0.83 (0.49-1.40) | .483 | ||
| SD, PD | 24 | — | ||||
| Duration of treatment with BTKi, mo | >6 | 36 | 0.68 (0.41-1.12) | .128 | ||
| ≤6 | 34 | — | ||||
| Reason for stopping BTKi | PD | 59 | 1.21 (0.58-2.52) | .611 | ||
| Toxicity | 12 | — | ||||
| Duration of treatment with last therapy before venetoclax, mo | >4 | 35 | 0.68 (0.42-1.11) | .125 | ||
| ≤4 | 43 | — | ||||
| Venetoclax highest dose received, mg | ≥400 | 59 | 1.20 (0.64-2.25) | .571 | ||
| <400 | 17 | — | ||||
| Venetoclax combined with other agents | Yes | 31 | 0.67 (0.40-1.10) | .115 | ||
| No | 49 | — |
Variables with <50% data capture were excluded from the MVA.